ABF customs reality — what gets seized at the AU border, and what gets through

Two sets of rules apply at the border. For personal use, the TGA Personal Importation Scheme sets the conditions: personal or immediate-family use, at most a 3-month supply, and a valid Australian prescription or written authority for a prescription-only medicine. Separately, the Customs (Prohibited Imports) Regulations 1956 (regulation 5G, Schedule 7A) prohibit importing growth hormones, insulin-like growth factors, growth hormone releasing hormones and their synthetic analogues, gonadotrophins, erythropoietin and anabolic or androgenic substances without written permission from the Department of Health, Disability and Ageing. These are "tier 1 goods", and importing them without that permission is an offence under section 233BAA of the Customs Act 1901 (up to 5 years' imprisonment, 1,000 penalty units, or both). TGA says non-compliant imports may be seized and destroyed and can lead to fines or civil or criminal proceedings.

For individual buyers, PeptideGuide has no official source on what ABF does with a held parcel, on any notice period, or on follow-up action.

Packaging and declarations: PeptideGuide has no data on how declarations or packaging affect interception, and does not recommend misdescribing goods or concealing them in packaging.

The Special Access Scheme and the Authorised Prescriber scheme are sometimes described as institutional research routes. They are for registered health practitioners treating patients and do not cover laboratory research purchases (TGA SAS guidance).

For non-institutional Australian researchers, PeptideGuide has no data on how often parcels are intercepted or what happens to them. The one vendor with an AU warning on PeptideGuide (Pharma Lab Global) carries it because its listing states that TGA Schedule 4 controls apply and research-use-only labelling does not exempt the shipment, not because of interception data.

More from this region.

Other articles covering this region's vendors, regulatory framework, and research peptides.

• 2026-10-31Earlier versions said two tracked vendors carry AU warnings. One (Pharma Lab Global) does.
• 2026-10-13Earlier versions listed "individual buyer enforcement is typically seizure-only, not prosecution" as a point in buyers' favour. PeptideGuide holds no data on enforcement outcomes; the claim was removed.
• 2026-10-12Earlier versions described Customs Act s233BAA as the prohibited-imports section for therapeutic goods, said therapeutic goods need a permit or the Personal Importation Scheme, that the scheme requires a product registered elsewhere, and that the Special Access Scheme and Authorised Prescriber scheme are institutional research routes that research labs use routinely, with ABF clearing SAS-approved shipments without delay. They also said buyers typically get 28 days to produce a permit or prescription and that most face no further action after a seizure. s233BAA applies to tier 1 goods listed in the Customs regulations, the scheme has no registered-elsewhere condition, and TGA describes the SAS as patient access through a health practitioner. The text was corrected with links to TGA and legislation.gov.au.
• 2026-10-08Earlier versions said UK-origin parcels clear Australian customs more often than US- or China-origin ones, that honest "research chemical" declarations are intercepted more than "supplement" ones, that repeated orders are expected-value-positive, that buyers typically face seizure with no follow-up, and that the SAS pathway has zero interception risk, all without a source. PeptideGuide found no source and holds no delivery data, so these claims were removed.